Cook Medical (Bloomington, Indiana) said it will have a significantly expanded vendor relationship with HealthTrust Purchasing Group (Brentwood, Tennessee). Cook is now contracted to supply medical devices in the areas of peripheral diagnostics, peripheral intervention, vena cava filters and peripheral stents to HealthTrust's member facilities.

Freescale Semiconductor (Orlando) and Monebo Technologies (Austin, Texas) have forged a partnership to deliver a comprehensive platform for medical equipment using electrocardiogram (ECG) technology. The "ECG-on-a-chip" solution combines Monebo's Kinetic ECG software with Freescale's embedded processing technology to enable medical equipment manufacturers to develop easy-to-use ECG monitoring tools. To help healthcare professionals assess cardiac parameters, Monebo Technologies has developed the Kinetic ECG algorithm, which enables signal processing and interpretation of the ECG waveform. The algorithm provides highly accurate QRS (Q wave, R wave and S wave) detection and feature extraction, beat classification, interval measurement and rhythm interpretation for up to 16 leads of captured ECG data. Monebo's Kinetic software runs on a broad range of Freescale microprocessors and microcontrollers. These processing platform options give developers freedom of choice for their ECG applications, based on their performance, operating power, integration and system cost needs.

HemCon Medical Technologies (Portland, Oregon) reported it will use SanguiBioTech's (Witten, Germany) ChitoSkin technology platform to help further innovations in hemostatic bandages and wound care dressings for the acute-care market. HemCon retains exclusive worldwide market and distributing rights for products developed under this structured financial agreement. HemCon will submit developed products for U.S. approvals to the FDA, while Sangui will prepare documentation for registration in the European Union. SanguiBioTech focuses on vascular and hemostasis products. The firm specializes in developing oxygen-carrying agents to treat blocked arteries, anemia or acute blood loss.

LifeScan (Milpitas, California), maker of the OneTouch Brand of blood glucose meters for people with diabetes, and ResMed (Poway, California), a manufacturer of devices for the diagnosis and treatment of sleep apnea, reported an exclusive co-marketing agreement designed to improve the lives of people with Type 2 diabetes and sleep-disordered breathing (SDB). The joint work of the two companies will focus on educational and cross-promotional efforts intended to benefit the patients and healthcare professionals served by both companies. The goal is to build awareness among healthcare professionals of the overlap of these two conditions, trigger new approaches to patient care, and ultimately improve the rate of treating patients suffering from both SDB and diabetes. LifeScan is a Johnson & Johnson (New Brunswick, New Jersey) company and a maker of blood glucose monitoring products.

IDev Technologies (Houston) a developer of minimally invasive stent systems for the treatment of peripheral vascular and non-vascular diseases, reported an exclusive distribution agreement with YMed (San Diego) for sales of the VascuTrak 2 Focal Force PTA Catheter in North America and select European markets. The VascuTrak 2 Focal Force PTA Catheter has been engineered for the dilatation of stenoses of the peripheral vasculature and is available in a broad range of diameter sizes and lengths to address this challenging anatomy. It is approved for use in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries and for the treatment of obstructive lesions of native synthetic arteriovenous dialysis fistulae. The Focal Force design concentrates the forces from balloon inflation along two axial dimensions to achieve safe and effective dilatation of both soft and calcified lesions at lower balloon inflation pressures. As a result, it is believed that the incidence of barotrauma may be reduced.

Positron (Houston) and Disease Management have agreed to co-develop a coronary artery disease prevention and reversal software program and total disease management solution. The product will include a heart disease pre-test risk calculator, a Coronary Disease Reversal and Prevention practice management program, a web-based, patient centric, disease reversal and life style modification program, an interpreting and referring physician portal, as well as a cost efficacy and patient outcomes tracker. "The development of our heart disease management solution will help us reach beyond our current molecular imaging targeted business to offer a product to payers, self-insured corporations, multi-specialty groups, cardiology groups, hospitals and finally direct to the consumer," said Joseph Oliverio, president of Positron. Positron also reported that it has entered into an exclusive sales and marketing agreement with NuView Radiopharmaceuticals (Park City, Utah). NuView Radiopharmaceuticals will act as exclusive agent for Positron's brand of PET, SPECT and automated dose-dispensing systems. NuView has an established network of 35 salespeople strategically located across the country. Positron develops cardiac molecular imaging technology.